Teva Pharmaceutical Industries Ltd Receives New Coverage from Analysts at ISI Group (TEVA)
Stock analysts at ISI Group started coverage on shares of Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group initiated coverage on shares of Teva Pharmaceutical Industries Ltd in a research note on Tuesday, August 5th. They set a “buy” rating and a $62.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Teva Pharmaceutical Industries Ltd in a research note on Monday, August 4th. They now have a $57.00 price target on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Teva Pharmaceutical Industries Ltd from $55.70 to $58.00 in a research note on Friday, August 1st. They now have a “hold” rating on the stock. Eight research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $58.39.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) traded down 2.83% on Thursday, hitting $51.15. The stock had a trading volume of 6,485,566 shares. Teva Pharmaceutical Industries Ltd has a 52-week low of $36.26 and a 52-week high of $55.70. The stock has a 50-day moving average of $52.93 and a 200-day moving average of $51.37. The company has a market cap of $43.667 billion and a P/E ratio of 17.34.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) last announced its earnings results on Thursday, July 31st. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.02. The company had revenue of $5.00 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter in the previous year, the company posted $1.20 earnings per share. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $4.93 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a dividend of $0.353 per share. This represents a $1.41 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Tuesday, August 19th.
Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA) is an Israel-based pharmaceutical and drug company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.